Compositions and methods for achieving immune suppression

Details Compositions and methods for achieving immune suppression Compositions and methods for achieving immune suppression

2004-05-25

2008-03-25

Kemmerer, Elizabeth C. (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

C424S085200, C435S069500, C435S069520, C435S069700, C435S071100, C530S351000

Reexamination Certificate

active

07347995

ABSTRACT:
Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.

REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5552303 (1996-09-01), Grabstein et al.
patent: 5574138 (1996-11-01), Grabstein et al.
patent: 5707616 (1998-01-01), Grabstein et al.
patent: 5747024 (1998-05-01), Grabstein et al.
patent: 5892001 (1999-04-01), Grabstein et al.
patent: 19823351 (1998-12-01), None
patent: WO 88/07089 (1988-09-01), None
patent: WO 93/08207 (1993-04-01), None
patent: WO 93/19770 (1993-10-01), None
patent: WO 94/04180 (1994-03-01), None
patent: WO 94/04570 (1994-03-01), None
patent: WO 94/17773 (1994-08-01), None
patent: WO 95/06480 (1995-03-01), None
patent: WO 95/06481 (1995-03-01), None
patent: WO 95/06666 (1995-03-01), None
patent: WO 95/27722 (1995-10-01), None
patent: WO 95/28957 (1995-11-01), None
patent: WO 96/16665 (1996-06-01), None
patent: WO 96/23071 (1996-08-01), None
patent: WO 96/26274 (1996-08-01), None
patent: WO 9626274 (1996-08-01), None
patent: WO 96/40246 (1996-12-01), None
patent: WO 97/17446 (1997-05-01), None
patent: WO 97/20063 (1997-06-01), None
patent: WO 97/22256 (1997-06-01), None
patent: WO 97/26000 (1997-07-01), None
patent: WO 97/34633 (1997-09-01), None
patent: WO 9741232 (1997-11-01), None
patent: WO 98/01145 (1998-01-01), None
patent: WO 98/52606 (1998-11-01), None
patent: WO 98/56417 (1998-12-01), None
patent: WO 98/58672 (1998-12-01), None
patent: WO 99/00143 (1999-01-01), None
patent: WO 99/12566 (1999-03-01), None
Mijares et al, Molecular Pharmacology, 2000, vol. 58, pp. 373-379.
Boulougouris et al, The Journal of Immunology, 1998. vol. 161, pp. 3919-3924.
Lin, et al.The Role of Shared Receptor Motifs and Common Stat Proteins in the Generation of Cytokine Pleiotropy and Redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15.Immunity, 2:331-339 (Apr. 1995).
Morrison, et al.Structural Determinants of Human IgG Function. The Immunologist 2(4):119-124 (1994).
Brekke, et al.Structure-Function Relationships of Human IgG.The Immunologist 2(4):125-130 (1994).
Pettit, et al.Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling. The Journal of Biological Chemistry 272(4): 2312-2318 (1997).
Stevens, et al.Interleukin-15 signal, T84 colonic epithelial cells in the absence of the interleukin-2 receptor β-chain. Am. J. Physiol. 272:G1-G8 (1997).
Armitage, et al.IL-15 Has Stimulatory Activity for the Induction of B Cell Proliferation and Differentiation. Journal of Immunology 154:483-490 (1995).
Chae, et al.Distribution of IL-15 Receptor α-Chains on Human Peripheral Blood Mononuclear Cells and Effect of Immunosuppressive Drugs on Receptor Expression. Journal of Immunology 157:2813-2819 (1996).
Moreland, et al.Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor(p75)-Fc Fusion Protein. N. Engl. J. Med 337(3):141-147 (1997).
Elliott, et al.Repeated therapy with monoclonal antibody to tumor necrosis factor α(cA2)in patients with rheumatoid arthritis. Lancet 344(8930):1125-1127 (1994).
Elliott, et al.Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α(cA2)versus placebo in rheumatoid arthritis. Lancet 344(8930):1105-1110 (1994).
Williams, et al.Successful therapy of collagen-induced arthritis with TNF receptor-IfG fusion protein and combination with anti-CD4. Immunology 84(3): 433-439 (1995).
Wooley, et al.Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice. Journal of Immunology 151(11):6442-6607 (1993).
Vey, et al.IFN-γ and 1,25(OH)2D3Induce on THP-1 Cells Distinct Patterns of Cell Surface Antigen Expression, Cytokine Production, and Responsiveness to Contact with Activated T Cells. Journal of Immunology 149(6):2040-2046 (1992).
Courtenay, et al.Immunisation against heterologous type II collagen induces arthritis in mice.Nature 283(5748): 666-668 (1980).
Burger, et al.Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases I in synociocytes and fibroblasts upon direct contact with stimulated T Lymphocytes. Arthritis & Rheumatism 41(10):1748-1759 (1998).
Kim, et al.Targeting the IL-15 Receptor with an Antagonist IL-15 Mutant/Fcγ2a Protein Blocks Delayed-Type Hypersensitivity. Journal of Immunology 160:5742-5748 (1998).
Li, et al.Induction of Allograft Tolerance in the Absence of Fas-Mediated Apoptosis.Journal of Immunology 163:2500-2507 (1999).
Kim, et al.Targeting the IL-15 Receptor with an Antagonist IL-15/Fcγ2a Protein BlocksDTH and Enhances the Acceptance of Islet Allografts. 17thASTP (Physicist) Annual Meeting, Chicago, IL May 9-13, 1998 (p. 713).
Kirk, et al.Treatment of humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates.Nature Medicine 5(6):686-693 (1999).
Nickerson, et al.Prolonged islet allograft acceptance in the absensce of interleukin 4 expression.Transplant Immunology 4:81-85 (1996).
Lakkis, et al.Interleukin 4 receptor targeted cytotoxicity: genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein. Eur. J. Immunol. 21:2253-2258 (1991).
Li, et al.Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance.Nature Medicine 5(11):1298-1302 (1999).
Agostini et al.,Blood, v93 (No. 4), pp. 1277-1286 (Feb. 1999).
Ferrari-Lacraz et al.,Jrl. Of Immuno., v167 (No. 6), pp. 3478-3485 (Se. 2001).
Kim et al.,Jrl. Of Immuno.,v160 (No. 12), pp. 5742-5748 (Je. 1998).
Kim et al.,Transplantation Proceedings, v30 (No. 8), pp. 4031-4036 (1998).

Affiliated with

Also associated with

Rating

Compositions and methods for achieving immune suppression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for achieving immune suppression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for achieving immune suppression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3974360